Intensity Therapeutics (INTS) Presents Positive INT230-6 Data

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. SMCI
8. RTX
9. S
10. COF

Go back to Intensity Therapeutics (INTS) Presents Positive INT230-6 Data

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023

November 2, 2023 7:01 AM EDT

The disease control rate for subjects in the monotherapy was 93% for patients who received at least one dose of INT230-6

INT230-6 extended survival in refractory soft tissue sarcoma subjects by nearly 15 months when compared to a synthetic control group

In the study, INT230-6 was found to have a favorable safety profile and be well tolerated, with approximately 90% adverse events being grade 1 or 2

WESTPORT, Conn., Nov. 2,... More